Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Breast Neoplasms 1

Interventions

Trastuzumab 546 Paclitaxel 504 Cyclophosphamide 484 Docetaxel 427 Capecitabine 367 Letrozole 330 Fulvestrant 288 Doxorubicin 259 Tamoxifen 244 Carboplatin 240 Anastrozole 207 Radiotherapy 200 exemestane 196 Epirubicin 178 Bevacizumab 174 palbociclib 164 Lapatinib 154 pertuzumab 151 Vinorelbine 151 Gemcitabine 149 pembrolizumab 144 Surveys and Questionnaires 122 Exercise 117 Magnetic Resonance Spectroscopy 113 eribulin 106 Fluorouracil 105 Albumin-Bound Paclitaxel 105 Blood Specimen Collection 102 130-nm albumin-bound paclitaxel 95 Everolimus 93

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡